tirzepatide vs semaglutide clinical trials 2026: 22% vs 15% Weight Loss Guide My - SURPASS-2: A Study

It just works on fat

Clinical trials have demonstrated substantial efficacy for tirzepatide in both glycemic control and weight reduction

The company has a market capitalization of roughly $500 million

The expanding role of therapeutic antibodies

At present, the studies of EX on non-diabetic obesity mainly include 152 cases of simple obesity (weight loss of 5.1 kg) (54), 60 cases of polycystic ovary syndrome (weight loss of 3.2-6.0 kg) (55), and 10 cases of metabolic syndrome (weight loss of 3.7 kg) (56), among which the most common adverse reaction is still vomiting

It is sometimes prescribed off-label for weight loss